Education
Gratz College Launches America’s First Master’s Degree in Antisemitism Studies
PHILADELPHIA, February 22, 2024 (Newswire.com) - Gratz College is launching the first Master of Arts degree program in Antisemitism Studies in the United States in Fall 2024. This ground-breaking program will help fill the vacuum of knowledge about antisemitism across Jewish, non-Jewish, and governmental organizations responsible for generating policy to combat prejudice at a time of unprecedented Jew hatred.
It will:
• Provide an academic home for those seeking to develop both a deep theoretical and practical understanding of antisemitism;
• Help generate new and impactful research on the factors that contribute to growing antisemitism and test interventions that can successfully combat it; and
• Arm educators and practitioners with the most effective antisemitism pedagogy and programming.
Through degree concentrations in teaching, advocacy and research, graduates of this program will be uniquely qualified for prominent careers in education, think tanks, government relations, public policy, and community organizations (Jewish and non-Jewish).
Pennsylvania Governor Josh Shapiro is eager to see this program take shape:
“We’re seeing a dangerous rise in antisemitism, hatred, and bigotry across our country – and it’s more important than ever that Pennsylvanians be equipped with a thorough knowledge of our shared history and the skills to discern fact from fiction. Gratz College is already renowned for its Holocaust and Genocide Studies programs, and I am encouraged the College is expanding upon that work with a new Master’s degree in Antisemitism Studies. I wish the faculty, staff, and especially the inaugural class of Antisemitism Studies students, great success in their work.”
The program is directed by Dr. Ayal Feinberg, antisemitism studies expert and Director of the Center for Holocaust Studies and Human Rights at Gratz College. The program boasts a distinguished interdisciplinary faculty from academia and leading public advocacy organizations. Despite its infancy, the degree has been endorsed by nearly one hundred scholars and public policy experts from around the world. Professor of Political Science at Kalamazoo College R. Amy Elman asserts, “With an emphasis on operationalizing knowledge, informed teaching and ethical advocacy, Gratz’s innovative graduate program fulfills a deep need in countering antisemitism.”
Gratz’s Antisemitism Studies program is also establishing ground-breaking partnerships with the world’s most prominent Jewish organizations and programs to combat antisemitism in the classroom, on campus, and in professional workspaces. In the first such partnership, Gratz and The Weitzman National Museum of American Jewish History have joined forces to launch the National Education Fellowship on Antisemitism. The aim of this fellowship is to generate and assess paradigm-shifting middle and high school curriculum to reduce Jew-hatred and prejudice more broadly.
As an early adopter of online education, a 128-year history of Jewish learning, and home to the world’s largest graduate program in Holocaust and Genocide Studies, Gratz is uniquely qualified to take on this necessary and overdue program.
On March 4, 2024, the master’s degree program will kick-off with a series of public lectures, including by scholars serving as affiliate faculty for the program. On April 2, 2024, Dr. Avinoam Patt, inaugural director of NYU’s Center for Study of Antisemitism and the Maurice Greenberg Professor of Holocaust Studies, will deliver a keynote lecture, titled, "Awake My People": Jewish Responses to Antisemitism in the Modern Period.” Additional talks will take place before the program officially begins in August.
Prospective students eager to start may apply now and take courses as early as March 2024 with electives in Antisemitism Studies already developed as a preview to the program.
Gratz College is grateful to the Isidore and Penny Myers Foundation for generously supporting the launch of the Antisemitism Studies program. Jay Myers, Board Chair, shared: “The Isidore and Penny Myers Foundation, a family foundation guided by Jewish American values, sees great worth in educating future generations about the roots of Antisemitism, and by doing so, working to combat it. This degree program will create scholars who can devote their talent to meet this challenge. Our Foundation is proud to support this work and by so doing, meet our obligation to help repair the world.”
Contact: lcohen@gratz.edu for more information.
Contact Information:Lori Cohen
Director of Marketing and Design
lcohen@gratz.edu
215-635-7300 x182
Original Source: Gratz College Launches America's First Master's Degree in Antisemitism Studies
Latest Fit News
Fort Brewery and Hell’s Half Acre Stadium Goods Join Forces to Launch Hell’s Half Lager, a Collaboration Benefiting the Flying T Club
FORT WORTH, Texas, July 25, 2023 (Newswire.com) - Fort Brewery, a locally-owned brewery, and Hell's Half Acre Stadium Goods, a licensed apparel company, are excited to announce their partnership and the release of a new beer collaboration called Hell's Half Lager. This special brew has been crafted with a purpose, as a portion of all sales will go towards supporting the Flying T Club and its student-athlete ambassadors.
Hell's Half Lager's name is a nod to the Wild West history of Fort Worth and Hell's Half Acre. This name resonates with all three partners as they trailblaze their industry, focusing on supporting the community and creating a best-in-class experience for their customers and ambassadors.
The Flying T Club is an organization dedicated to fostering the growth and development of student-athletes in our community. They provide opportunities for young individuals to excel in their chosen sports while emphasizing the importance of education and character development. By offering comprehensive support, including scholarships, training facilities, and mentorship programs, the Flying T Club enables student-athletes to achieve their full potential both on and off the field.
Hell's Half Lager represents a perfect blend of Fort Brewery's expert craftsmanship and Hell's Half Acre Stadium Goods' passion for Fort Worth sports. This crisp and refreshing lager has been meticulously brewed using the finest ingredients to deliver a flavor profile that appeals to beer enthusiasts and sports fans alike. With its smooth finish and balanced taste, Hell's Half Lager is set to become a favorite among beer lovers. Fort Brewery describes the Lager as an easy-drinking stadium beer perfect for the hottest of gamedays.
Jack Feltgen, Project Lead at Fort Brewery & a former cheerleader at TCU, describes Hell's Half Lager as the project he has been vying for since graduation: "To build a beverage brand that allows fans to have an accessible means to support their team is very exciting to me. As someone whose role in athletics was to unite fans and build enthusiasm during gameday, I believe HHL perfectly encapsulates my former role on campus, and as an alumnus, give back to those same opportunities I had as a student-athlete on campus."
As part of the collaboration, Fort Brewery and Hell's Half Acre Stadium Goods will host a series of events and promotional activities to raise awareness about the Flying T Club and the Hell's Half Lager. These events will provide opportunities for individuals to learn more about the Flying T Club's initiatives, interact with student-athletes, and enjoy the fantastic flavors of Hell's Half Lager.
"We are proud to partner with Fort Brewery in supporting the Flying T Club," stated Steven Stults, Founder of Hell's Half Acre Stadium Goods. "The collaboration represents our shared commitment to empowering student-athletes and providing them with the resources they need to succeed. Hell's Half Lager is not just a beer; it is a symbol of community support."
Hell's Half Lager will be available for purchase at Fort Brewery, as well as select retailers, bars, and restaurants starting August 3rd. Beer enthusiasts and supporters of the Flying T Club are encouraged to look out for Hell's Half Lager and join the movement to make a difference in the lives of student-athletes.
Contact Information:Jack Feltgen
Project Lead
jackf@fk1935.com
219-309-6273
Aaron Hoernke
Marketing Director
aaronh@fk1935.com
9202031892
Original Source: Fort Brewery and Hell's Half Acre Stadium Goods Join Forces to Launch Hell's Half Lager, a Collaboration Benefiting the Flying T Club
Early Announcement of Significantly Beneficial Clinical Trial Evidence From Young Blood Plasma Treatments
HOUSTON, July 25, 2023 (Newswire.com) - Golden Gift, a 501(c)(3) nonprofit organization in support of the therapeutic use of blood plasma from young donors in treating age-related conditions, has shared an early announcement of significantly beneficial clinical trial evidence for Fresh Frozen Plasma (yFFP) Treatments. Chronic conditions developing in our aging population are now currently accounting for 90% of the United States' health care costs. A frightening fact for the youth of our country is that health care expenses for these patients are expected to reach $5 trillion by 2025. Who will pay for it? Band-aid medication is not the answer. In fact, the greatest risk factor for disease is the degeneration of the body that develops as we age. The real resolution of age-associated diseases arises from insights into understanding and supporting the fundamental biology of age changes.
All animate and inanimate matter have the same universal molecular etiology. The science of physics indicates that genes do not drive the aging process, but the general loss of molecular organization does. Every organ and blood vessel in our body as we undergo our basic metabolism, replacement, and repair, experiences a movement towards spreading out or loss of energy. For example, hot coffee gets cold, balls roll down hill and 3-dimensional complex molecules cannot be created with accuracy indefinitely. Therefore, large organs and metabolic functions fail, and can no longer support the existence of the organism.
Age changes occur in every multicellular animal. As the system starts to lose the ability to create complex matricellular proteins, non-structural proteins that support cell function, it begins losing the ability to 'run the system' - your body. Longevity is determined by the ability to maintain the potential energetics of all molecules.
How long can one continue to make the necessary complex structures as the laws of physics work to break us down? Waves of changes in the dysfunctional proteome of the blood in the fourth, seventh, and eighth decades of life reflect this degeneration: https://pubmed.ncbi.nlm.nih.gov/31806903. As less optimal complex usable proteins begin to circulate through the blood stream, the body becomes less efficient and as a result, we age, and we get sick: https://pubmed.ncbi.nlm.nih.gov/31932806.
The removal of old cells and other debris, such as through the apheresis process, may in-fact, slow degeneration, and create some immune modulation, and cell stimulation. Everyone can use modalities of calorie restriction, exercise, and supplements to enhance the functions of their cells. However due to the Second Law of Thermodynamics, eventually complex molecules within the milieu cannot be produced any longer and must be replaced:
https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1395.001
Young blood plasma, collected from sex-identified individuals between the ages of 18 - 25, reverses age-related profiles and initiates systemic rejuvenation by introducing 10K proteins, 5K peptides, 45 cytokines, 50 sex matched hormones and 1.84 billion exosomes per ml, along with minerals and gut microbiota metabolites from healthy volunteer donors at the peak of their reproductive maturity. What your body can no longer make, you can replace and really slow the aging process, enhance fitness, and ward off disease.
This concept is illustrated in patients with cardiac disease. Those with heart failure will produce higher levels of BNP (brain natriuretic peptide) due to the stress on the muscle and overall cardiac function. A 79-year-old male had his BNP drop from over 1,300 pg/ml to 705 pg/ml after a 2-liter exchange, and a 71-year-old male with severe heart failure saw his BNP drop from 6,800 pg/ml to 715 pg/ml with 1-liter of his old plasma out, and 3-liters from young donors in, over two days.
Aging is now understood as a gradual, progressive deterioration simultaneously affecting different organ systems. Those with a faster 'Pace of Aging' tend to experience more rapid aging-related declines in physical and cognitive functions, have a higher predisposition to disease, and an accelerated time to death. We call these epigenetic changes. "Genetics loads the gun, but environment shoots it."
Evidence suggests that interventions to slow Pace of Aging will slow the progression to disease development and works to extend health/life span. The DunedinPACE is a highly accurate and reliable single-time-point measure of methylation that quantifies an individual's Pace of Aging by evaluating their present state health to different biological processes of a population that was followed for age changing markers over time.
Epigenetic changes that slow aging are difficult to realize and maintain. Prolonged significant calorie restriction was shown to reduce DunedinPACE by only 2-3% after two years: https://doi.org/10.1038/s43587-022-00357-y. Clearly, an overall healthy exercise plan as part of anyone's lifestyle has also been proven to reduce the rate of aging. However, due to the laws of physics, interventions without adding young molecules only work to a point.
A DunedinPACE of 1 was established to reference an average rate of 1 year of biological aging per year of chronological aging. Among Dunedin Study participants, the range of values extends from just above 0.6 (indicating an aging rate nearly 40 percent slower than the norm) to nearly 1.4 (indicating an aging rate 40 percent faster than the norm).
Sensitive to all interventions, the DunedinPACE very importantly allows testing of treatments intended to extend health span and lifespan in humans. For example, a 67-year-old male participating in our study with Parkinson's disease received 2.5-liters of young Fresh Frozen Plasma (yFFP) through three exchanges within thirty days. In four months, his DunedinPACE was reduced by 18% to 0.82.
A similarly significant outcome was realized in four months by a 78-year-old female with a family history and personal signs of dementia. She received 1.8-liters of young plasma in two-infusions, reducing her DunedinPACE by 17% to 0.78.
Making an early announcement of significantly beneficial clinical trial documentation from an ongoing study is important from many viewpoints: clinicians practicing evidence-based medicine; future patients to whom the studies apply; patients currently participating in clinical trials; and scientists, investigators, and regulators who strive to balance continuing studies with disseminating data in confirmation of therapeutic advances as quickly as is reasonable.
Our Investigational young Fresh Frozen Plasma (yFFP) Treatments Study continues to treat patients in the major cities in Texas by more than a dozen IRB-registered Co-Investigators. Additional outcomes will be presented at RAADfest in September and at the A4M World Congress in December.
https://www.youngplasmastudy.com
https://www.youtube.com/@dianginsbergmd-optimalhealth
All research in the United States involving human subjects must be reviewed by an Institutional Review Board (IRB), unless specifically exempted by a federal regulation. Review boards protect the rights, privacy, and health of the research subjects in determining research will be conducted in a safe and ethical manner.
The Institute of Regenerative and Cellular Medicine
Barbara Krutchkoff, PhD., Executive Director
barbara@ircm.org / Phone: (888) 664-8893
IRB Registration Number: IRB00009500
IRB Parent/Organization Number: IORG0007913
Dian Ginsberg, MD
Principle Investigator
dianginsberg.md@gmail.com
(281) 569-4289
Related Files
Golden Gift Parkinson's Disease study.pdf
Ginsberg YP042022v2 9.31.22 Approval.pdf
Original Source: Early Announcement of Significantly Beneficial Clinical Trial Evidence From Young Blood Plasma Treatments
